A phase Ib/II open-label study of tazemetostat (TAZ) plus enzalutamide (E) or abiraterone/prednisone (A/P) in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

Wassim Abida,Thomas Bradley,Arash Rezazadeh,Lawrence Ivan Karsh,Ashley E. Ross,Daniel R. Saltzstein,Evren Kocabas Argon,Anthony Hamlett,Jeanie Tang,Deyaa Adib

A phase Ib/II open-label study of tazemetostat (TAZ) plus enzalutamide (E) or abiraterone/prednisone (A/P) in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

2020

Wassim Abida
Thomas Bradley
Arash Rezazadeh
Lawrence Ivan Karsh
Ashley E. Ross
Daniel R. Saltzstein
Evren Kocabas Argon
Anthony Hamlett
Jeanie Tang
Deyaa Adib

TPS255Background: The histone methyltransferase EZH2 is overexpressed in many cancers. In prostate cancer (PC), EZH2 inhibition may reverse acquired resistance to androgen inhibitors (AIs). Pts may...

Keywords:

Castration
Prednisone
Prostate cancer
Oncology
Pathology
Abiraterone
Medicine
Chemotherapy
Internal medicine
Enzalutamide
Tazemetostat
Androgen inhibitor
EZH2
open label study
chemotherapy naive
Histone methyltransferase

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations